

Rozanolixizumab-noli (Rystiggo)

Provider Order Form rev. 1/25/2026



- Saint Cloud, FL
- Lake Mary-Sanford, FL
- Nashville, TN
- Gallatin, TN

PATIENT INFORMATION

Referral Status: New Referral Updated Order Order Renewal

Date: _____ Patient Name: _____ DOB: _____

ICD-10 code (required): _____ ICD-10 description: _____

NKDA Allergies: _____ Weight (lbs/kg): _____ Height: _____

Patient Status: New to Therapy Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

PROVIDER INFORMATION

Referral Coordinator Name: _____ Referral Coordinator Email: _____

Ordering Provider: _____ Provider NPI: _____

Referring Practice Name: _____ Phone: _____ Fax: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

NURSING

Provide nursing care per IVCare Infusion's Nursing Procedures, including reaction management and post-procedure observation

NOTE: IVCare Infusion's Adverse Reaction Management Protocol available upon request

LABORATORY ORDERS

- CBC at each dose every _____
- CMP at each dose every _____
- CRP at each dose every _____
- OTHER _____

PREMEDICATIONS

- acetaminophen (Tylenol) 500 mg 650 mg 1000 mg PO
 - cetirizine (Zyrtec) 10mg PO
 - loratadine (Claritin) 10mg PO
 - diphenhydramine(Benadryl) 25 mg 50 mg PO IV
 - methylprednisolone (Solu-Medrol) 40mg 125mg IV
 - hydrocortisone (Solu-Cortef) 100mg IV
- Other: _____
- Dose: _____ Route: _____

THERAPY ADMINISTRATION

Rozanolixizumab-noli (Rystiggo)
Dose

- Weight Less than 50kg: 420mg
- 50kg to less than 100kg: 560mg
- 100kg and above: 840mg

Frequency: once weekly for six weeks (one treatment cycle)
Route: subcutaneous infusion

Select for additional treatment cycles.

_____ (Indicate number of cycles)

Subsequent cycles may require additional insurance authorization.

Treatment cycles will be given 63 days from the start of the previous treatment cycle.

Administer as a subcutaneous infusion.

Monitor patients during administration and for 15 minutes after completion for clinical signs and symptoms of hypersensitivity reactions. Order will expire one year from date signed.

CLINICAL INFORMATION (If available)

MG-ADL Score: _____ MGFA Classification: _____

AChR or MuSK antibodies: Yes No

MENINGITIS VACCINE:

Patient HAS received first dose of both Conjugate (MenACWY) and Serogroup B (MenB) vaccines Yes No

(If No, complete the following):

- Office will administer MenACWY and MenB Vaccines
- IVCare Infusion to Administer Meningococcal conjugate (MenACWY) Vaccine and Serogroup B Meningococcal (MenB) Vaccine:
Menactra OR Menveo - two doses separated by 8 weeks AND Bexsero - 2 doses separated by 1 month OR Trumenba - 3 doses at 0, 1-2 and 6 months. Vaccines will be given 2 weeks prior to starting Rystiggo infusion. If urgent Rystiggo administration is needed in unvaccinated patient, please contact us at (615) 471-8673

SPECIAL INSTRUCTIONS

Provider Name (Print) _____ Provider Signature _____ Date _____

Email info@ivcareinfusion.com or fax this Form, Insurance card (both sides), Demographics, Recent H&P, Labs & supporting Clinicals to:

FAX NUMBER FOR RYSTIGGO REFERRALS: (615) 471-8674

TN

NASHVILLE

5501A NEW YORK AVE, NASHVILLE, TN. 37209
P: 615-475-5657 F: 615-475-5680

GALLATIN

710 NASHVILLE PIKE, STE 103, GALLATIN, TN. 37066
P: 615-471-8673 F: 615-471-8674

FL

ST. CLOUD

2801 13TH STREET, ST. CLOUD, FL. 34769
P: 407-477-2345 F: 615-471-8674

LAKE MARY - SANFORD

344 W. LAKE MARY BLVD, SANFORD, FL. 32773
P: 407-477-2345 F: 615-471-8674